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of diagnostics for global health 
should collaborate to leverage their 
respective resources and expertise, 
thereby enhancing the likelihood of 
development of HCV diagnostics. 
A broad coalition of stakeholders 
such as diagnostic-focused product-
development partnerships, donors, 
governments, WHO, and Ministries of 
Health, among others, will be needed. 
This approach was taken in the Ebola 
outbreak and should shorten the 
development timeline for a successful 
test. Product-development partners 
have already embarked on this path 
in other settings and should be 
encouraged to do so for HCV. 
Unfortunately, in the absence 
of a concerted effort to fund HCV 
diagnostics, the global health 
community will find itself faced 
with little eﬀ ect of the development 
in treatment options and an ever-
increasing morbidity and mortality 
from HCV that will drain the scarce 
resources that low-resource countries 
have for the health of its citizens.
CMD is employed by the Foundation for Innovative 
New Diagnostics (FIND), a non-proﬁ t organisation 
that collaborates with industry partners for the 
development, assessment, and demonstration of 
new diagnostic tests for poverty-related diseases. 
MK is the chairman of FIND.
Copyright © Denkinger et al. Open access article 
distributed under the terms of CC BY.
*Claudia M Denkinger, Mark Kessel
claudia.denkinger@ﬁ nddx.org
FIND, 1211 Geneva 20, Switzerland (CMD, MK); 
Division of Infectious Disease, Beth Israel Deaconess 
Medical Center, Boston, MA, USA (CMD); Shearman 
& Sterling, London, UK (MK); and Symphony Capital 
LLC, New York, NY, USA (MK)
1 Mohd Hanaﬁ ah K, Groeger J, Flaxman AD, 
Wiersma ST. Global epidemiology of hepatitis 
C virus infection: new estimates of age-speciﬁ c 
antibody to HCV seroprevalence. Hepatology 
2013; 57: 1333–42.
2 Kamal-Yanni M. Hepatitis C drug aﬀ ordability. 
Lancet Glob Health 2015; 3: e73–74.
3 UNITAID. Hepatitis C medicines and 
diagnostics in the context of HIV/HCV 
co-infection: a scoping report. Geneva: 
UNITAID, 2013.
4 Smith BD, Drobeniuc J, Jewett A, et al. 
Evaluation of three rapid screening assays for 
detection of antibodies to hepatitis C virus. 
J Infect Dis 2011; 204: 825–31.
Diagnostics for 
hepatitis C: an urgent 
need for action
Hepatitis C virus (HCV) is a global 
health problem with an estimated 
130–150 million people infected and 
350 000–500 000 deaths annually,1 
most of which occur in low-income 
or middle-income countries. As drug 
prices decrease and new treatments 
become more aﬀ ordable, as outlined 
by Mohga Kamal-Yanni2 (February 
issue), there is an opportunity for 
high-burden countries to prioritise 
their activities against this disease.
One of the lessons the global 
health community learned from its 
experience with HIV was the need 
to rapidly identify individuals who 
are eligible for treatment. Yet HCV 
is severely underdiagnosed (<1% of 
the infected population in limited 
resource settings).3 Diagnostic tests 
are complex and expensive, and can 
only be performed at centralised 
laboratories, which are few and far 
between in low-resource settings; 
some of the available tests (eg, rapid 
tests) for HCV detection are of poor or 
unknown quality.4
Simple algorithms for diagnosis 
need to be integrated into the 
established workflow and fit-for-
purpose tests for decentralised use 
(eg, a novel core-antigen test at low 
cost to provide a one-step solution 
for diagnosis) must be developed. 
Meanwhile, there is a need to 
improve both quality and speciﬁ city 
of serological tests sub-Saharan Africa 
(due to cross-reactivity).
Major donors must be better 
informed of the importance of 
diagnostics in the fight against 
HCV. An understanding of the 
economic value of HCV diagnostics 
will foster investments in diagnostic 
development. Although there is 
an appreciation of the effect of 
reliable diagnostics on treatment, 
the value in the reduction of the 
overall cost to health systems in 
low-resource settings is unfortunately 
underappreciated. To date, most 
funding for general diagnostic 
development in low-resource 
countries comes from the public 
sector and from the Bill and Melinda 
Gates Foundation. The global 
health community needs to come 
together to devise strategies that 
will attract more funding into HCV 
diagnostics. For example, industries 
with a high incidence of HCV among 
its employees have an economic 
incentive to promote the health 
of their employees and should be 
encouraged to contribute funding. 
Governments in endemic countries 
need to be convinced to contribute 
to diagnostic development, either 
by providing funding or donation of 
resources, such as clinical trial support 
in governmental facilities.
For a diagnostic to be appropriate 
in low-resource countries, it needs 
to be affordable, accurate, user-
friendly, robust, and ideally also rapid 
(particularly at the point-of-care). 
Manufacturers can be incentivised 
via access to scientiﬁ c and regulatory 
expertise through organisations such 
as the Foundation for Innovative New 
Diagnostics, which help to reduce 
the cost and development time. 
This strategy has been effective for 
tuberculosis diagnostics, exemplified 
by the successes of the Xpert MTB/
RIF assay (Cepheid). Organisations 
involved in diagnostics for low-
resource settings have developed 
close ties with Ministries of Health 
and can provide substantial support 
in the implementation of novel HCV 
diagnostics in the public and private 
sectors. This assistance is of paramount 
importance to the less well capitalised 
or nascent manufacturers in high-
resource settings as well as in low-
income countries. Financial incentives 
can be created to guarantee appropriate 
returns on manufacturers’ investments. 
Knowledge transfer can also be 
considered to ensure aﬀ ordable prices.
Organisations that have been 
successful in fostering development 
